

## DAFTAR PUSTAKA

- Ahmed, K. *et al* .2010. *Extended spectrum  $\beta$ -lactamase mediated resistance in Escherichia coli in a tertiary care hospital in Kashmir, India. Afr. J. Microbiol. Res*; 5(2): 2721-2728.
- Al-Jasser, Asma M. 2006. *Extended-Spectrum Beta-Lactamases (ESBLs): A Global Problem. Kuwait Medical Journal*, 38 (3) : 171-185.
- Adisasmito AW & Tumbelaka AR. 2006 penggunaan antibiotik khususnya pada infeksi bakteri gram negatif di ICU anak RSAB Harapan Kita. *Sari Pediatri*, 8(2): 127-134. Jakarta : Fakultas Kedokteran Universitas Indonesia.
- Anonim.2008. WHO Fact Sheet (<http://www.oneworldhealth.org>).
- Andini, Sari. 2010. Pola Resistensi Isolat Bakteri Pada Luka Post Operasi Seksio Sesarea di Bagian Obstetri dan Ginekologi RSUD Dr. Abdul Moeloek Bandar Lampung. (Skripsi). Universitas Lampung. 66 hlm.
- Babini GS, Livermore DM .2000. *Antimicrobial resistance amongst Klebsiella spp collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother*; 45: 183-9.
- Brooks, Geo F.; Butel, Janet S.; Morse, Stephen A. 2008. *Mikrobiologi Kedokteran Edisi 23*. Jakarta : EGC.
- Behroozi, A. *et al* .2010. Frequency of *extended spectrum beta-lactamase (ESBLs) producing Escherichia coli and klebsiella pneumonia* isolated from urine in an Iranian 1000-bed tertiary care hospital. *Afr. J. Microbiol. Res*:5(2) : 881-884
- Bhattacharjee, A, Sen MR, Prakash P .2008. Increased Prevalence of ESBL on Neonatal Septicemic Cases at Tertiary Referral Hospital. In *J Med. Microbiol*;26(4) :356-60.
- Bronzwaer, SL., Cars, O., Buchhols, U., Molstad, S., Goettsch, W., *et al* .2002. A European Study on The Relationship between Antimicrobial Use and Antimicrobial Resistance, *Emerging Infectious Disease* () 8 : 278-282.

- Carol. A .2007. *Firs Generation of Cephalosporine: summary of the first international symposium. J Antimicrob Chemother. Clin Microbiol Rev*; 14:933-951.
- Chaudhary, U., Aggarwal R. 2004. *Extended-Spectrum  $\beta$ -Lactamases (ESBL) – An Emerging Threat to Clinical Therapeutics. Indian Journal of Medical Microbiology*. (<http://medind.nic/iau/t04/i2>, diakses tanggal 2 Oktober 2011).
- Chandra, Angela. 2004. Efektivitas Beberapa Antibiotika Sebagai Alternatif Pemberian Terapi Untuk *Escherichia coli* dan *Klebsiella pneumonia* Penghasil *Extended Spectrum Beta Lactamase* (ESBL). (Tesis). Universitas Indonesia. Jakarta. 65 hlm.
- Chaikittisuk, Napaporn and Anurak Munsrichoom. 2007. *Extended-Spectrum  $\beta$ -Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in Children at Queen Sirikit National Institute of Child Health. Journal Infectious Diseases Antimicrobial Agents. Vol. 24 No. 3 .p.107-115.*
- Cotton MF, Wasserman E, Pieper CH .2002. *Invasive disease due to extended-spectrum  $\beta$ -lactamase producing Klebsiella pneumonia in a neonatal unit: the possible role of cockroaches. J Hosp Infect*; 44: 13-7.
- D’Azevedo PA, Goncalves ALS, Musskopf MI, Ramos CG, Dias CAG .2004. *Laboratory tests in the detection of extended spectrum  $\beta$ -Lactamase production: National Committee for Clinical Laboratory Standards (NCCLS) screening test, the Etest, the double disk confirmatory list., Braz. J. Infect. Dis., 8(5): 372-377.*
- Duttaroy B, Mehta S .2005. *Extended spectrum  $\beta$ -lactamase (ESBL) in clinical isolates of Klebsiella pneumoniae and Escherichia coli. Indian J. Pathol. Microbiol., 48(1): 45-48.*
- Dubreuil, J.D .2002. *Escherichia coli STb enterotoxin, Microbiology,143; 1783–1795.*
- Erdian, Defi. 2012. Pola Resistensi Terhadap Antibiotik Pada Bakteri Penyebab Sepsis Neonatorum di Rumah Sakit Abdul Moeloek. (Skripsi). Universitas Lampung. 60 hlm.
- Eslava, C. F. Navarro-García, J.R. Czeczulin, I.R. Henderson, A. Cravioto, J.P. Nataro, Pet, .2009. *an autotransporter enterotoxin from enteroaggregative Escherichia coli, Infect. Immun. 66 3155–3163.*
- Fraser VJ, Kollef MH. 2006 antibiotic resistance in the intensive care unit. *Ann Intern Med*, 123 : 298-314.

- Farmer III, J. J., Boatwright, K.D., Micheal Janda, J. 2007. Enterobacteriaceae; Introduction and Identification, p. 649-669. In P.R. Murray, Baron, E.J., Jorgensen, J.H., Pfaller, M.A., Tenover, R.H., (ed.), *manual of clinical microbiology*, 9th ed, vol. 1. ASM Press, Washington, D.C.
- Goodman & Gilman. 2008. *Dasar Farmakologi terapi. Penerbit Buku Kedokteran*. EGC. Jakarta.
- Herwana, Elly., Yenny., Laurentia Pudjiadi., Julius E. Surjawidjaja., Murad Lesmana. 2008. *Prevalence Of Extended spectrum beta-lactamase in Klebsiella pneumoniae*. Univ Med : 27 : 98-105.
- Hardjoeno. 2007. *Kumpulan Penyakit Infeksi dan Tes Kultur Sensitifitas Kuman Serta Upaya Pengendaliannya*. Cahya DINan Rucitra. Makassar. Hal 158-165.
- Harbarth SJ, Pittlet D. 2007. The intensive care unit: part a. HAI epidemiology, surveillance, engineering and administrative infection control practices, and impact. In: Jarvir WR (editor). *Bennet and brachman's hospital infection*: 375-393. Ed. 5th. Philadelphia: lippincot Williams and Wilkins.
- Iroha, I.R., et al.2009. *Extended Spectrum beta-lactamase (ESBL) in E. coli isolated from a tertiary hospital in Enugu State, Nigeria*. *Pak. J. Med. Sci.*, 25: 279-288.
- Jawetz, E.; Melnick J.; Aldenberg E. 2005. *Mikrobiologi Kedokteran*. Jakarta : EGC, pp: 357-359.
- Jabeen K, Zafar A, Hasan R. 2005. Frequency and sensitivity pattern of extended spectrum  $\beta$ -Lactamase producing isolates in a tertiary care hospity laboratoty of pakistan. *J. Pak med. Assoc.*, 55(10): 436-439.
- Jitsurong, Siroj and Jareerat Yodsawat. 2006. Prevalence of Extended –Spectrum Beta Lactamases (ESBL) Produced in Blood Isolates of Gram-negatif Bacteria in a Teaching Hospital in Southern Thailand. *Southeast Asian Journal Trop Med Public Health*. Vol 37 No. 1. p.131-135.
- Karch, H .2001. *The role of virulence factors in enterohemorrhagic Escherichia coli (EHEC) associated hemolytic uremic syndrome*, *Semin. Thromb. Hemost.* 27 ;207–214.
- Karowsky J A. et. al. 2010. *Multidrug resistant urinary tract isolates of Escherichia coli : prevalence and patient demographics in the United states in 2009*. *Antimicrob Agents Chemother* 2009; 45(5) : 1402-06.

- Katzung, Bertram G. 2010. *Farmakologi Dasar dan Klinik Edisi 10*. EGC, Jakarta. hlm 747.
- Kollef MH. 2006. Time to get serious about infection prevention in the ICU. *Chest* : 130 : 1293-1296.
- Livermore DM. 2005.  *$\beta$ -lactamases in laboratory and clinical resistance*. *Clin Microbiol Rev*; 8: 557-84.
- Levinson. Warren. 2008. *Review of Medical Microbiology and Immunologi Tenth edition*. Mc Graw-hill, New York.
- Maliku, Palupi. 2010. *Pola Resistensi Isolat Bakteri Pada Luka Post Operasi di Bagian Rawat Inap Bedah RSUD Dr. H. Abdul Moeloek Bandar Lampung*. (Skripsi). Universitas Lampung. 66 hlm.
- Mycek, 2006. *Farmakologi Ulasan bergambar*, : 304-329. Jakarta : Widya Medika.
- Naber KG, Carson C. 2004. *Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections.*; 64 (12): 1359-73.
- Nathisuwan S., Burgess D.S., Lewis II J.S. 2005. *ESBLs : Epidemiology, Detection and Treatment*. *Pharmacotherapy*. 21(8): 921-928.
- National Committee for Clinical Laboratory Standards. 2005. *Performance standards for antimicrobial susceptibility testing; 15<sup>th</sup> informational supplement (M100-S15)*. *National Committee for Clinical Laboratory Standards*, Wayne, Pa.
- Nelwan RHH. 2002. *Pemakaian antimikroba secara rasional di klinik*. Dalam: Noer S, editor. *Buku ajar ilmu penyakit dalam*. Jakarta : Balai Penerbit FKUI;: 537-540.
- Olowe, O.A., Aboderin, B.W. 2010. *Detection of Extended Spectrum-Lactamase producing strains of (Escherichia coli) and (Klebsiella sp.) in a Tertiary health Centre in Ogun State*. *Int j of trop Med.*, 5(3): 62-64.
- Parsot C. 2005. *Shigella spp. and enteroinvasive E. coli pathogenicity factors*, *FEMS Microbiol. Lett.* 252 8–11.
- Paterson, David L., Bonomo, Robert A. 2010. *Extended-Spectrum  $\beta$ -Lactamases : a Clinical Update*. *Clinical Microbiology Review vol 18*. pp:657-686 (<http://cmr.asm.org/cgi/content/full/18/4/657>, diakses tanggal 4 Oktober 2011).
- Prescott, L.M., Harley, J.P Klein D.A. 2008. *Microbiology*, William C. Brown Publishers, Dubuque, IA, USA pp. 415–476.

- Petri Jr WA. *Penicillin, cephalosporins and Other  $\beta$ -lactam antibiotics*. Dalam : Goodman & Gillman's, *The Pharmacological Basis of Therapeutics*, edisi XI. 1127-2254, 2006.
- Prabaningrum, N. dan Septiana V. 2008. *Cefotaxime*. (<http://yosefw.wordpress.com/2008/03/> Diakses tanggal 16 Oktober 2011).
- Prescott, L.M., Harley, J.P Klein D.A. 2008. *Microbiology*, William C. Brown Publishers, Dubuque, IA, USA pp. 415–476.
- Rupp .M. E. and Paul D. F. 2003. *Extended Spectrum  $\beta$ -Lactamase (ESBL) Producing Enterobacteriaceae Considerations for Diagnosis, Prevention and Drug Treatment*. Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA : 354-362
- Saragih, Iwan. 2012. Uji Keberadaan *Enzim Extended Spectrum  $\beta$ -Lactamase (ESBL)* pada *Klebsiella sp.* Dari Isolat Klinik Rumah Sakit Umum Abdul Moeloek dan Laboratorium Kesehatan Daerah Bandar Lampung. (Skripsi). Universitas Lampung. 38 hlm.
- Saepudin, Pajariu .2007. *Perbedaan penggunaan antibiotika pada pengobatan pasien infeksi saluran kemih yang menjalani rawat inap di salah satu RSUD di Yogyakarta: Media Medika Indonesia*. Fakultas Kedokteran Universitas Diponegoro. 260 – 67.
- Sharma S, *et. al.* 2007. Virulence factors and Drug resistance in *Escherichia coli* isolated from extra intestinal infections. *Indian J Med Microbiol*; 25 (4) : 369-373.
- Samuel, Erich J. 2012. Uji Keberadaan *Enzim Extended Spectrum  $\beta$ -Lactamase (ESBL)* pada *Escherichia coli* Dari Isolat Klinik Rumah Sakit Umum Abdul Moeloek dan Laboratorium Kesehatan Daerah Bandar Lampung. (Skripsi). Universitas Lampung. 48 Hlm.
- Smyth EG, O'Connell N .2004. *Complicated urinary tract infection*. *Drugs & Therapy Perspectives*; 11(1): 63-6.
- Severin, Julieete A., Ni Made Mertaniasih ., Kuntaman Kuntaman ., Endang S. Lestari., Marijam Purwanta., Nicole Lemmens. *et al.* Molecular Characterization of *Extended Spectrum  $\beta$ -Lactamase* in Clinical *Escherichia coli* and *Klebsiella pneumoniae* Isolates From Surabaya, Indonesia. 2010. *Journal Antimicrobial Chemoteraphy*. 65 : 465-469.
- Tsang DNC. Que TL, Ho M, Yuen K Y .2007. Comparison of Screening Methods for detection of ESBL and their prevalence among *E. coli* and *Klebsiella sp* in Hongkong. *APMIS*.;108;23.40.

- Tumbarello M .2010. *Bloodstream Infections Caused by Extended-Spectrum-beta-Lactamase-Producing Klebsiella pneumoniae: Risk Factors, Molecular Epidemiology, and Clinical Outcome*; (<http://aac.asm.org/cgi/reprint/50/2/498>. diakses tanggal 28 November 2011).
- Urba'nek, K., M. Kolar., Y. Lovec'kova., J. Strojil., L. Santava. 2007. Influence of third-generation cephalosporin utilization on the occurrence of ESBL-positive *Klebsiella pneumoniae* strains. *Journal of Clinical Pharmacy and Therapeutics*. 32: 403–408.
- Whittam, T.S. et. al.2011. *Pathogenesis and evolution of virulence in enteropathogenic and enterohemorrhagic Escherichia coli*, *J. Clin. Invest.*107;539–548.
- Willey, J., Sherwood, L., Woolverton, C. 2008. Prescott, Harley, & Klein's *Microbiology*, 7 ed. McGraw-Hill, New York, New York.
- Winarto. 2009. Prevalensi Kuman ESBL (*Extended Spectrum Beta Lactamase*) dari Material darah di RSUP Dr. Kariadi Tahun 2004-2005. *Media Medika Indonesia*, Vol. 43 No: 260-268.